[Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
Chronic kidney disease (CKD) is an important risk factor for end-stage renal disease (ESRD) and cardiovascular events as well. Early-onset and progressive atherosclerosis is common in patients with CKD, which is caused by varieties of factors including dyslipidemia. CKD-related dyslipidemia such as increased triglyceride-rich atherogenic lipoproteins such IDL, small dense LDL and low HDL associated with insulin resistance, oxidative stress, inflammation, and malnutrition co-existing dyslipidemia such as high LDL are both causetive for early-onset atherogenesis and, possibly progression of CKD, thus are the therapeutic targets in early intervention of CKD. Life-style modification aimed for both renoprotection and anti-dyslipidemia as well as medications for metabolic disorders in CKD patients such as Ca/P imbalance is crucial for correction of dyslipidemia, and also prevention of cardiovasclular events and ESRD in CKD patients. Among anti-dyslipidemic drugs, statin, so far, is only class of drug proved to be effective for such purpose on evidence-basis.
Watanabe
Tsuyoshi
T
Department of Internal Medicine 3, Fukushima Medical University School of Medicine.
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D002908:Chronic Disease; D018450:Disease Progression; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology* / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000517:prevention & control*; D008019:Life Style
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents